Dharwad News Today

Propulsion of Oral Mucositis Clinical Trial Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Domain | DelveInsight

 Breaking News
  • No posts were found

Propulsion of Oral Mucositis Clinical Trial Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Domain | DelveInsight

August 22
06:05 2023
Propulsion of Oral Mucositis Clinical Trial Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight’s assessment, globally, the Oral Mucositis Pipeline constitutes 10+ key companies continuously working towards developing 10+ Oral Mucositis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Oral Mucositis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Oral Mucositis NDA approvals (if any), and product development activities comprising the technology, Oral Mucositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Oral Mucositis Pipeline treatment landscape of the report, click here @ Oral Mucositis Pipeline Outlook

 

Key Takeaways from the Oral Mucositis Pipeline Report

  • DelveInsight’s Oral Mucositis Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
  • The leading companies are working in the Oral Mucositis Market include Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics, and others.
  • Promising Oral Mucositis Pipeline Therapies in the various stages of development include Benzydamine, Dentoxol, RRx-001, IZN-6N4, SGX942, Ectoin Mouth Wash, GC4419 90mg, Melatonin oral gel 3%, Clonidine Lauriad® 50µg, amlexanox, and others.
  • On February 2023, E2Bio Life Sciences LLC announced a study of phase 1 & 2 clinical trials for Benzydamine and Bocaliner. Group 1 will receive standard therapy with conventional oral care to prevent oral mucositis consisting of oral hygiene and rinses/mouthwashes with saline solutions 3-5 times daily.
  • On April 2023, Galera Therapeutics Inc announced a study of phase 3 clinical trials for GC4419 90mg. The purpose of the phase 3, clinical study is to determine if GC4419 (avasopasem manganese) administered prior to intensity-modulated radiation therapy (IMRT) reduces the severity of radiation induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck.

 

Oral Mucositis Overview

Mucositis occurs when cancer treatments break down the rapidly divided epithelial cells lining the gastro-intestinal tract (which goes from the mouth to the anus), leaving the mucosal tissue open to ulceration and infection. Mucosal tissue, also known as mucosa or the mucous membrane, lines all body passages that communicate with the air, such as the respiratory and alimentary tracts, and have cells and associated glands that secrete mucus.

 

For further information, refer to the detailed Oral Mucositis Unmet Needs, click here for Oral Mucositis Ongoing Clinical Trial Analysis

 

Oral Mucositis Emerging Drugs Profile

 

  • GC4419: Galera Therapeutics

GC4419, also known as avasopasem manganese, has successfully completed two clinical trials in which it was evaluated for reduction of severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The drug is currently in phase III stage of clinical trial evaluation to treat Oral Mucositis.

 

  • SGX942: Soligenix

SGX942 is unique in its mechanism addressing the underlying innate immune dysfunction that contributes to the severity and duration of mucositis. Administered twice weekly by a brief 4-minute IV infusion during chemoradiation treatment while patients are otherwise present at their clinician’s office or hospital, SGX942 may be a clinically convenient and safe approach to mitigating oral mucositis. Company’s pivotal Phase 3 clinical study (“DOM-INNATE”) for oral mucositis in head and neck cancer patients has completed enrollment.

 

Oral Mucositis Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Oral Mucositis. The Oral Mucositis companies which have their Oral Mucositis drug candidates in the most advanced stage, i.e. phase III include, Soligenix.

 

Request a sample and discover the recent advances in Oral Mucositis Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Oral Mucositis Segmentation

 

Oral Mucositis Drugs and Companies

  • Melatonin oral gel 3%: Spherium Biomed
  • Clonidine Lauriad® 50µg: Onxeo
  • Amlexanox: Access Pharmaceuticals Inc.
  • Soluble beta-1,3/1,6-glucan: Biotec Pharmacon ASA

 

Oral Mucositis Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Oral Mucositis Therapeutics Market include-

Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics, and others.

 

Dive deep into rich insights for drugs for Oral Mucositis Pipeline, click here @ Oral Mucositis Unmet Needs and Analyst Views

 

Scope of the Oral Mucositis Pipeline Report

  • Coverage- Global
  • Oral Mucositis Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics, and others.
  • Oral Mucositis Therapies- Benzydamine, Dentoxol, RRx-001, IZN-6N4, SGX942, Ectoin Mouth Wash, GC4419 90mg, Melatonin oral gel 3%, Clonidine Lauriad® 50µg, amlexanox, and others.
  • Oral Mucositis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Oral Mucositis Merger and acquisitions, Licensing Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Oral Mucositis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Oral Mucositis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. SGX942: Soligenix
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MIT-001: MitoImmune Therapeutics
  12. Drug profiles in the detailed report…..
  13. Inactive Products
  14. Oral Mucositis Key Companies
  15. Oral Mucositis Key Products
  16. Oral Mucositis- Unmet Needs
  17. Oral Mucositis- Market Drivers and Barriers
  18. Oral Mucositis- Future Perspectives and Conclusion
  19. Oral Mucositis Analyst Views
  20. Oral Mucositis Key Companies
  21. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Categories